title: [Influence of metformin and N-acetylcysteine on hormonal and genotoxic effects of estrogens and glucose in convalescent cancer patients].
abstract: Our study involved 25 postmenopausal patients (endometrial carcinoma--16, breast (6) and colorectal (3) cancer, aged 56.8 +/- 0.9). All patients were in clinical remission. None had received any specific therapy for at least 12 months. After a laboratory endocrine-genotoxic switch evaluation, 17 patients were given an antidiabetic drug--biguanide metformin--or N-acetylcysteine as antioxidant (8) for 3 months. A checkup was carried out on completion of the course. As a result, hormonal and progenotoxic effects of glucose were found to be inhibited significantly. Much less pronounced was the impact on relevant effects of estradiol which were investigated vis-a-vis nature of blood mononuclear response in vitro. Both isolated and combined administration of said drugs used for endocrine-metabolic rehabilitation is justified.
authors.forename: L M
authors.initials: LM
authors.lastname: Bershteĭn
authors.forename: D A
authors.initials: DA
authors.lastname: Vasil'ev
authors.forename: T E
authors.initials: TE
authors.lastname: Poroshina
authors.forename: I G
authors.initials: IG
authors.lastname: Kovalenko
authors.forename: M P
authors.initials: MP
authors.lastname: Boiarkina
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Revskoĭ
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Kovalevskiĭ
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000378:metabolism; D003110:Colonic Neoplasms / Q000378:metabolism; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000378:metabolism*; D017698:Postmenopause; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001786:Blood Glucose; D004967:Estrogens; D016166:Free Radical Scavengers; D007004:Hypoglycemic Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D008687:Metformin; D005947:Glucose; D000111:Acetylcysteine